Deals in Depth: November 2009
Executive Summary
In an alliance worth $849 million in pre-commercialization money, BMS added another rheumatoid arthritis therapeutic to its pipeline, Alder's Phase IIa ALD518. The top two pharma M&As were in the specialty pharmaceutical space--Biovitrum/Swedish Orphan and Enzon/Sigma-Tau. Meanwhile, Stryker got into the medical device reprocessing market via its acquisition of Ascent. And pharma and device financing were both down from the previous month (although October did boast several big outlier deals).